H.C. Wainwright Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
H.C. Wainwright's Patrick Trucchio reiterated a Buy rating for Voyager Therapeutics with a $25.00 price target. Shares closed at $4.23. Trucchio, a 5-star analyst, has a 27.1% average return and 51.33% success rate. The consensus rating for Voyager Therapeutics is Strong Buy with a $14.00 average price target.
In a report released yesterday, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Voyager Therapeutics, with a price target of $25.00. The company’s shares closed yesterday at $4.23.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
According to TipRanks, Trucchio is a 5-star analyst with an average return of 27.1% and a 51.33% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Aligos Therapeutics, and Altimmune.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Voyager Therapeutics with a $14.00 average price target.
